434 related articles for article (PubMed ID: 2648877)
1. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
[TBL] [Abstract][Full Text] [Related]
2. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].
Chenard-Neu MP; Bellocq JP; Maier A; Batzenschlager A
Ann Pathol; 1990; 10(1):20-7. PubMed ID: 2328062
[TBL] [Abstract][Full Text] [Related]
3. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
4. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
5. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
Sheibani K; Battifora H; Burke JS
Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.
Wirth PR; Legier J; Wright GL
Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354
[TBL] [Abstract][Full Text] [Related]
7. DNA ploidy analysis of pleural mesotheliomas: its usefulness for their distinction from lung adenocarcinomas.
Esteban JM; Sheibani K
Mod Pathol; 1992 Nov; 5(6):626-30. PubMed ID: 1369798
[TBL] [Abstract][Full Text] [Related]
8. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE
Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302
[TBL] [Abstract][Full Text] [Related]
9. [Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].
Galateau-Salle F
Arch Anat Cytol Pathol; 1993; 41(5-6):212-22. PubMed ID: 8135582
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.
Moch H; Oberholzer M; Dalquen P; Wegmann W; Gudat F
Virchows Arch A Pathol Anat Histopathol; 1993; 423(1):19-27. PubMed ID: 8212530
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical and histochemical markers of primary lung cancer, lung metastases, and pleural mesotheliomas.
Popper H; Wirnsberger G; Hoefler H; Denk H
Cancer Detect Prev; 1987; 10(3-4):167-74. PubMed ID: 2436780
[TBL] [Abstract][Full Text] [Related]
12. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of membranous staining of mesothelioma.
King JA; Tucker JA
Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
[TBL] [Abstract][Full Text] [Related]
14. Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies.
Tuttle SE; Lucas JG; Bucci DM; Schlom J; Primus J
J Surg Oncol; 1990 Oct; 45(2):72-8. PubMed ID: 2214794
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical properties of malignant mesothelioma cells in histologic and cytologic specimens.
Motoyama T; Watanabe T; Okazaki E; Tanaka N; Watanabe H
Acta Cytol; 1995; 39(2):164-70. PubMed ID: 7534025
[TBL] [Abstract][Full Text] [Related]
16. A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas.
Khoury N; Raju U; Crissman JD; Zarbo RJ; Greenawald KA
Hum Pathol; 1990 Aug; 21(8):811-9. PubMed ID: 1696923
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
[TBL] [Abstract][Full Text] [Related]
18. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
Brown RW; Clark GM; Tandon AK; Allred DC
Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
[TBL] [Abstract][Full Text] [Related]
19. Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1.
Warnock ML; Stoloff A; Thor A
Am J Pathol; 1988 Oct; 133(1):30-8. PubMed ID: 2845790
[TBL] [Abstract][Full Text] [Related]
20. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]